Trends in Mortality, Treatment, and Costs of Management of Acute Respiratory Distress Syndrome in South Korea: Analysis of Data between 2010 and 2019
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: Despite recent advances in the understanding and management of acute respiratory distress syndrome (ARDS), trendsin treatment, mortality, and healthcare costs following these advancements remain to be identified. In the present study, weaimed to investigate these trends using real-world data from a national cohort database in South Korea. Materials and Methods: Using the National Health Insurance Service database, we collected and analyzed data for critically illadult patients with ARDS who were admitted to intensive care units in South Korea between 2010 and 2019. Results: The final analysis included 25431 patients with ARDS. The 30-, 90-, and 365-day mortality rates in 2010 were 43.8%,56.5%, and 68.2%, respectively. These rates had gradually decreased to 36.6%, 50.2%, and 58.8%, respectively, by 2019. Extracorporealmembrane oxygenation support for patients with ARDS started in 2014 at a rate of 5.1% (118/2309), which gradually increasedto 8.3% (213/2568) by 2019. The rate of neuromuscular blockade treatment gradually increased from 22.6% (626/2771) in 2010 to30.9% (793/2568) in 2019. The renal replacement therapy rate gradually increased from 5.7% (157/2771) in 2010 to 12.0% (307/2568)in 2019. The mean total cost of hospitalization increased from 5986.7 USD in 2010 to 12336.4 USD in 2019. Conclusion: Real-world data for 2010–2019 indicate that patients with ARDS in South Korea have experienced changes in mortality,treatment, and healthcare costs. Despite the increased financial burden, mortality among patients with ARDS has decreaseddue to advances in disease management.
Abstract
Purpose: Despite recent advances in the understanding and management of acute respiratory distress syndrome (ARDS), trendsin treatment, mortality, and healthcare costs following these advancements remain to be identified. In the present study, weaimed to investigate these trends using real-world data from a national cohort database in South Korea. Materials and Methods: Using the National Health Insurance Service database, we collected and analyzed data for critically illadult patients with ARDS who were admitted to intensive care units in South Korea between 2010 and 2019. Results: The final analysis included 25431 patients with ARDS. The 30-, 90-, and 365-day mortality rates in 2010 were 43.8%,56.5%, and 68.2%, respectively. These rates had gradually decreased to 36.6%, 50.2%, and 58.8%, respectively, by 2019. Extracorporealmembrane oxygenation support for patients with ARDS started in 2014 at a rate of 5.1% (118/2309), which gradually increasedto 8.3% (213/2568) by 2019. The rate of neuromuscular blockade treatment gradually increased from 22.6% (626/2771) in 2010 to30.9% (793/2568) in 2019. The renal replacement therapy rate gradually increased from 5.7% (157/2771) in 2010 to 12.0% (307/2568)in 2019. The mean total cost of hospitalization increased from 5986.7 USD in 2010 to 12336.4 USD in 2019. Conclusion: Real-world data for 2010–2019 indicate that patients with ARDS in South Korea have experienced changes in mortality,treatment, and healthcare costs. Despite the increased financial burden, mortality among patients with ARDS has decreaseddue to advances in disease management.
참고문헌 (28)
- ARDS Definition Task Force, "Acute respiratory distress syndrome : the Berlin definition", JAMA, 307, pp.2526~2533 (2012)
- Bellani G, "Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries", JAMA, 315, pp.788~800 (2016)
- Máca J, "Past and present ARDS mortality rates : a systematic review", Respir Care, 62, pp.113~122 (2017)
- Adhikari NK, "Critical care and the global burden of critical illness in adults", Lancet, 376, pp.1339~1346 (2010)
- Riviello ED, "Hospital incidence and outcomes of the acute respiratory distress syndrome using the Kigali modification of the Berlin definition", Am J Respir Crit Care Med, 193, pp.52~59 (2016)
- Tzotzos SJ, "Incidence of ARDS and outcomes in hospitalized patients with COVID-19 : a global literature survey", Crit Care, 24, pp.516~ (2020)
- Fan E, "Acute respiratory distress syndrome : advances in diagnosis and treatment", JAMA, 319, pp.698~710 (2018)
- Amato MB, "Driving pressure and survival in the acute respiratory distress syndrome", N Engl J Med, 372, pp.747~755 (2015)
- Zheng Z, "Neuromuscular blocking agents for acute respiratory distress syndrome : an updated meta-analysis of randomized controlled trials", Respir Res, 21, pp.23~ (2020)
- Combes A, "Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome", N Engl J Med, 378, pp.1965~1975 (2018)
- Peck TJ, "Recent advances in the understanding and management of ARDS", F1000Res, 8, pp.1959~ (2019)
- Li G, "Eight-year trend of acute respiratory distress syndrome : a population-based study in Olmsted County, Minnesota", Am J Respir Crit Care Med, 183, pp.59~66 (2011)
- von Elm E, "The Strengthening the Reporting of Observational Studies in Epidemiology(STROBE)Statement : guidelines for reporting observational studies", Int J Surg, 12, pp.1495~1499 (2014)
- Ike JD, "The association between acute respiratory distress syndrome hospital case volume and mortality in a U. S. cohort, 2002-2011", Crit Care Med, 46, pp.764~773 (2018)
- Combes A, "ECMO for severe ARDS : systematic review and individual patient data meta-analysis", Intensive Care Med, 46, pp.2048~2057 (2020)
- Natt BS, "Extracorporeal membrane oxygenation for ARDS : national trends in the United States 2008-2012", Respir Care, 61, pp.1293~1298 (2016)
- Roch A, "Extracorporeal membrane oxygenation for severe influenza A(H1N1)acute respiratory distress syndrome : a prospective observational comparative study", Intensive Care Med, 36, pp.1899~1905 (2010)
- Hyoung-Won Cho, "Trends in extracorporeal membrane oxygenation treatment from 2005 to 2018 in South Korea", Perfusion, 37(6), pp.545~552 (2021), SAGE Publications[DOI]
- Slutsky AS, "Neuromuscular blocking agents in ARDS", N Engl J Med, 363, pp.1176~1180 (2010)
- Puthucheary Z, "Neuromuscular blockade and skeletal muscle weakness in critically ill patients : time to rethink the evidence?", Am J Respir Crit Care Med, 185, pp.911~917 (2012)
- Wongtangman K, "Optimal sedation in patients who receive neuromuscular blocking agent infusions for treatment of acute respiratory distress syndrome-a retrospective cohort study from a New England Health Care Network", Crit Care Med, 49, pp.1137~1148 (2021)
- Moss M, "Early neuromuscular blockade in the acute respiratory distress syndrome", N Engl J Med, 380, pp.1997~2008 (2019)
- Papazian L, "Neuromuscular blockers in early acute respiratory distress syndrome", N Engl J Med, 363, pp.1107~1116 (2010)
- Ho ATN, "Neuromuscular blockade in acute respiratory distress syndrome : a systematic review and meta-analysis of randomized controlled trials", J Intensive Care, 8, pp.12~ (2020)
- Han F, "Early initiation of continuous renal replacement therapy improves clinical outcomes in patients with acute respiratory distress syndrome", Am J Med Sci, 349, pp.199~205 (2015)
- Dill J, "Renal replacement therapy in patients with acute respiratory distress syndrome : a single-center retrospective study", Int J Nephrol Renovasc Dis, 11, pp.249~257 (2018)
- Wu N, "Healthcare costs utilization and costs of patients hospitalized with acute respiratory distress syndrome(ARDS)in US commercially-insured individuals and medicare beneficiaries", Eur Respir J, 46, pp.PA2139~ (2015)
- Scholten EL, "Treatment of ARDS with prone positioning", Chest, 151, pp.215~224 (2017)